Constant Expands Patent Portfolio for TXA127 and for Stroke
Boston, MA (March 27, 2018): Constant Pharmaceuticals, LLC, a privately held biopharmaceutical company focused on the treatment of stroke recovery, today announced that the European Patent Office (EPO) has notified the company that it will grant a patent covering the use of TXA127 in the treatment of stroke. TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide Angiotensin (1-7), which Constant is developing for the treatment of stroke recovery.
“This new patent is an important component of our strategy in developing a treatment for stroke recovery” said Richard Franklin, Chief Executive Officer of Constant Pharmaceuticals, LLC. “TXA127 has shown striking effects in three animal models of stroke recovery. Unlike tPA and other drugs attempting to target the acute stroke period, TXA127 can be given weeks to months after the stroke, and it leads to a return to near normal function that is permanent, even after the treatment is stopped. If these results can be replicated in our upcoming Phase 2 trial, there is the opportunity to transform the treatment and care of patients suffering from stroke.”
About 800,000 new cases of stroke occur annually in the U.S and another 1.1 million new cases in Europe. Approximately 3.5 million stroke survivors in U.S. and over 5 million stroke survivors in Europe have ongoing mobility issues, and there are no currently approved medications for such impairments.
Constant’s Chairman of the Advisory Board, Seth Finklestein, MD, commented, “The data to date indicate that TXA127 has the potential to help thousands of patients recovering from stroke.”
This EPO patent is the fourth issued patent covering the treatment of stroke for Constant. The company has previously received two issuances in the United States and a recent issuance in Japan. Constant plans to initiate the Phase 2 clinical trial in stroke recovery in early 2019.
About Constant Pharmaceuticals
Constant Pharmaceuticals LLC is a private biopharmaceutical company focused on the development of TXA127, a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1-7), for the treatment of stroke recovery. TXA127 has shown therapeutic activity in three animal models of stroke: tMCAO, pMCAO, and tMCAO plus common carotid. Constant Pharmaceuticals has broad IP protection for TXA127 and is planning a Phase 2 study in stroke recovery. For more information on Constant Pharmaceuticals, please visit our website at http://www.constanttherapeutics.com/.
Elizabeth Wagner, Vice President